Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B

Bibliography

• MAYNARD JE: Hepatitis B: global importance and need for control. Vaccine (1990) 8(Suppl.):S18–S20.
   Google Scholar
• DE JONGH FE, JANSSEN HL, DE MAN RA, HOP WC, SCHALM SW VAN BLANKENSTEIN M: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology (1992) 103:1630–1635.
   PubMed Web of Science ®Google Scholar
• EVANS AA, O'CONNELL AP, PUGH JC et al.: Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidennol Biomarkers Prey. (1998) 7:559–565.
   Google Scholar
• FATTOVICH G, BROLLO L, GIUSTINA G et al.: Natural history and prognostic factors for chronic hepatitis type B. Gut (1991) 32:294–298.
   PubMed Web of Science ®Google Scholar
• OHKUBO K, KATO Y, ICHIKAWA T et al.: Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer (2002) 94:2663–2668.
   PubMed Web of Science ®Google Scholar
• YANG HI, LU SN, LIAW YF et al: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl. I Med. (2002) 347:168–174.
   PubMed Web of Science ®Google Scholar
• LAI CL, CHIEN RN, LEUNG NW et al:A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Eng]. J. Med. (1998) 339:61–68.
   PubMed Web of Science ®Google Scholar
• LIAW YF, SUNG JJ, CHOW WC et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. (2004) 351:1521–1531.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, CHANG TT, LIM SG et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Eng]. J. Med. (2003) 348:808–816.
   PubMed Web of Science ®Google Scholar
• NIEDERAU C, HEINTGES T, LANGE S et al.: Long-term follow-up of HBeAg- positive patients treated with interferon alfa for chronic hepatitis B. N Engl. J. Med. (1996) 334:1422–1427.
   Google Scholar
• WONG DK, CHEUNG AM, O'ROURKE K, NAYLOR CD, DETSKY AS, HEATHCOTE J: Effect of a-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. (1993) 119:312–323.
   PubMed Web of Science ®Google Scholar
• LIAW YF, LEUNG N, GUAN R, LAU GK, MERICAN I: Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. Gastroenterol Hepatol (2003) 18:239–245.
   Google Scholar
• LOK AS, MCMAHON BJ: Chronic hepatitis B. Hepatology (2001) 34:1225–1241.
   PubMed Web of Science ®Google Scholar
• LAI CL, DIENSTAG J, SCHIFF E et al.: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. (2003) 36:687–696.
   PubMed Web of Science ®Google Scholar
• YUEN ME SABLON E, HUT CK, YUAN HJ, DECRAEMER H, LAI CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology (2001) 34:785–791.
   PubMed Web of Science ®Google Scholar
• LEUNG NW, LAI CL, CHANG TT et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 33:1527–1532.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, SCHIFF ER, WRIGHT TL et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl. J. Med. (1999) 341:1256–1263.
   PubMed Web of Science ®Google Scholar
• LIAW YF, CHIEN RN, YEH CT, TSAI SL, CHU CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology (1999) 30:567–572.
   PubMed Web of Science ®Google Scholar
• GAUTHIER J, BOURNE EJ, LUTZ MWet al.: Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J. Infect. Dis. (1999) 180:1757–1762.
   Google Scholar
• LOCARNINI SA: Clinical relevance ofviral dynamics and genotypes in hepatitis B virus. .1 Gastroenterol Hepatol (2002) 17\(Suppl. 3):5322–5328.
   Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl. J. Med. (2003) 348:800–807.
   PubMed Web of Science ®Google Scholar
• ANGUS P, VAUGHAN R, XIONG S et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 125:292–297.
   PubMed Web of Science ®Google Scholar
• PIERRA C, IMBACH JL, DE CLERCQ Eet al.: Synthesis and antiviral evaluation of some 13-L-2', 3'-dideoxy-5-chloropyrimidine nucleosides and pronucleotides. Antiviral Res. (2000) 45:169–183.
   Google Scholar
• BRYANT ML, BRIDGES EG, PLACIDI L et al.: Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Cheinother. (2001) 45:229–235.
   PubMed Web of Science ®Google Scholar
• SEIFER M, PATTY A, FARAJ A et al.: In vitro studies on the mechanism of action of L-nucleoside inhibitors of hepatitis B replication reveal differences between LdT and lamivudine. Antiviral Res. Hep. Dart. Abstracts (2001) (Abstract).
   Google Scholar
• STANDRING DN, BRIDGES EG, PLACIDI L et al: Antiviral 13-L-nucleosides specific for hepatitis B virus infection. Anti vir. Chem. Cheinother. (2001) 12\(Suppl. 1):119–29.
   Google Scholar
• HERNANDEZ-SANTIAGO B, PLACIDI L, CRETTON-SCOTT E et al: Pharmacology of P-L-thymidine and 3-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Cheinother. (2002) 46:1728–1733.
   PubMed Web of Science ®Google Scholar
• BRIDGES EG, CRETTON-SCOTT E, ZHOU XJ, JUODAWLKIS A, GOSSELIN G, BRYANT ML: The anti-HBV agent P-L-thymidine (LdT) exhibits no observable effects in chronic or developmental toxicity studies. Antiviral Res. Hep Dart Abstracts (2001) (Abstract).
   Google Scholar
• RAJAGOPALAN P, BOUDINOT FD, CHU CK, TENNANT BC, BALDWIN BH, SCHINAZI RF: Pharmacokinetics of ( ) 2' 3' dideoxy-3'-thiacytidine in woodchucks. Antimicrob. Agents Cheinother. (1996) 40:642–645.
   PubMed Web of Science ®Google Scholar
• VAN LEEUWEN R, LANGE JM, HUSSEY EK et al.: The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS (1992) 6:1471–1475.
   PubMed Web of Science ®Google Scholar
• ZHOU XJ, LIM SG, LAI CL, POW DM, BROWN NA, MYERS MW: Pharmacokinetics of P-L-deoxythymidine (LdT) in healthy subjects and patients with chronic hepatitis B virus infection. Antiviral Res. Hep Dart Abstracts (2001) (Abstract).
   Google Scholar
• LAI CL, LIM SG, BROWN NA, ZHOU XJ et al.: A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology (2004) 40:719–26.
   PubMed Web of Science ®Google Scholar
• ••This Phase I/II clinical study is the onlypublished article of telbivudine in human subjects. In this placebo-controlled, dose-escalating study of 4 weeks of therapy, telbivudine was reported to be well tolerated, with no associated adverse effects and a marked dose-related suppression of HBV replication was observed.
   Google Scholar
• NEUMANN AU, ZHOU XJ, BOEHME R et al.: Viral dynamics for LdT (telbivudine) reated hepatitis B patients: high degree of initial inhibition with dose-dependent second-phase HBV clearance suggests a new model for HBV dynamics. Hepatology (2004)40(4 Suppl. 1) (Abstract).
   Google Scholar
• LAI CL, LEUNG N, TEO EK et al: An international multicenter trial of LdT (Telbivudine), alone and in combination with lamivudine, for chronic hepatitis B: an interim analysis. Hepatology (2003) 36(4) (Abstract).
   Google Scholar
• LAI CL, LEUNG N, TEO EK et al: Results of a one-year international phase IIb comparative trial of telbivudine, lamivudine, and the combination in patients with chronic hepatitis B. Hepatology (2003)38(4 Suppl. 1):(Abstract).
   Google Scholar
• LEUNG NW, LAI CL, TEO EK et al: Results of a one-year international Phase IIb comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B. Hong Kong-Shanghai International Liver Congress. (2004) (Abstract).
   Google Scholar
• HAN SH, LEUNG NW, TEO EK et al.: Results of a one-year international Phase IIb trial of LdT, and LdT plus lamivudine, in patients with chronic hepatitis B. Hepatol (2004) 40(1): (Abstract)518Expert Op/n. Investig. Drugs (2005) 14(4)
   Google Scholar
• LAI CL, LEUNG NW, TEO EK et al: Improving antiviral therapy in chronic hepatitis B: maximal viral suppression at week 24 correlates with better clinical efficacy at one year. Hong Kong-Shanghai International Liver Congress. (2004) (Abstract).
   Google Scholar
• POYNARD T, LAI CL, LEUNG NW et al.: Improving antiviral therapy in chronic hepatitis B: maximal viral suppression at week 24 correlates with better clinical efficacy at one year. Hepatol (2004) 40(1):(Abstract).
   Google Scholar
• ZHOU XJ, MYERS M, CHAO GC, DUBUC G, BROWN NA: Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function. Hepatol (2004) 40(1).
   PubMedGoogle Scholar